Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Immunovant

Tracked across 2 events · 23 articles · First seen Apr 02, 2026 · Last active Sep 23, 2026

Sentiment
-42
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 -35
Tech
Immunovant announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The randomized, double-blind, placebo-controlled global study enrolled 57 adult patients who were randomized to IMVT-1402 or…
Impact: Immunovant is the central actor, reporting failed primary endpoint results for IMVT-1402 in CLE and deciding to stop development in that indication. The setback removes a pipeline opportunity but leaves other autoimmune programs on track.
Sep 23, 2026 · 7 articles
4 -50
Business
Impact: Immunovant's batoclimab Phase 3 studies failed to meet their primary endpoint for thyroid eye disease, which is a significant setback for the company.
Apr 02, 2026 · 16 articles
85 Immunovant reported topline resultsImmunovant IMVT-1402 CLE Trial Miss
ERGEN INTELLIGENCE
Track Immunovant live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.